Publisher retracts review article that says Ivermectin is effective against SARS CoV 2 virus | 出版商撤回稱伊維菌素對 SARS CoV 2 病毒有效的評論文章

Asiya Kamber Zaidi and Puya Dehgani-Mobaraki published in the Journal of Antibiotics on June 15, 2021, a comprehensive review on how antimalarial medication ivermectin works to prevent and treat SAR CoV 2 infection.

The superb review titled “The mechanisms of action of ivermectin against SARS CoV 2: An evidence-based clinical review article was quickly retracted by the Editor-in-Chief of the journal who claimed that while the mechanisms of action of ivermectin against SARS Cov 2 are clear, the sources cited in the review do not show clear clinical evidence which makes the EIC lose his or her confidence in the credibility of the review.

A note on the retraction says that either author agreed with the editor in chief.  That is, they believe that the evidence is strong to justify that Ivermectin works against SARS Cov 2.  In India, ivermectin is used commonly in an effort to stop the spreading of the SARS CoV 2.  India, the most populous country in the world, is one of the countries where SARS CoV 2 imposes the least damage to its citizens.  Many believe that the widespread use of ivermectin and hydroxychloroquine is the reason why the country to have a low infection incidence.

The withdrawal of this review article is in complete agreement with the current narrative on the efficacy of ivermectin at preventing SAR COV 2 infection.  In the U.S. doctors are banned from using this ivermectin to save Covid 19 patients.  Doctors and patients have to sue hospitals in order to use it.   This observation in a sense hints that ivermectin could be indeed very effective at preventing and treating covid 19.  In fact, hundreds of studies have proved ivermectin is highly effective at treating and preventing covid 19.

The following is the Abstract of the published review article.

Considering the urgency of the ongoing COVID-19 pandemic, detection of various new mutant strains and future potential re-emergence of novel coronaviruses, repurposing of approved drugs such as Ivermectin could be worthy of attention. This evidence-based review article aims to discuss the mechanism of action of ivermectin against SARS-CoV-2 and summarizing the available literature over the years. A schematic of the key cellular and biomolecular interactions between Ivermectin, host cell, and SARS-CoV-2 in COVID-19 pathogenesis and prevention of complications have been proposed.

Asiya Kamber Zaidi 和 Puya Dehgani-Mobaraki 於 2021 年 6 月 15 日在《抗生素雜誌》上發表了一篇關於抗瘧藥物伊維菌素如何預防和治療 SAR CoV 2 感染的綜合評論。

題為“伊維菌素對抗 SARS CoV 2 的作用機制：一篇循證臨床評論文章的精彩評論被該雜誌主編迅速撤回，他聲稱雖然伊維菌素對 SARS Cov 2 的作用機制很清楚，評論中引用的來源沒有顯示明確的臨床證據，這使得 EIC 對評論的可信度失去信心。

關於撤回的說明說，任何一位作者都沒有同意主編的意見。也就是說，他們認為有強有力的證據證明伊維菌素對 SARS Cov 2 有效。在印度，伊維菌素被普遍用於阻止 SARS CoV 2 的傳播。印度是世界上人口最多的國家，是 SARS CoV 2 對其公民造成最小損害的國家之一。許多人認為，伊維菌素和羥氯喹的廣泛使用是該國感染率低的原因。

這篇綜述文章的撤回與目前關於伊維菌素預防 SAR COV 2 感染功效的敘述完全一致。在美國，醫生被禁止使用這種伊維菌素來挽救 Covid 19 名患者。醫生和患者必須起訴醫院才能使用它。這一觀察結果在某種意義上暗示伊維菌素在預防和治療 COVID 19 方面確實非常有效。事實上，數百項研究證明伊維菌素在治療和預防 COVID 19 方面非常有效。

以下是已發表評論文章的摘要。

考慮到正在進行的 COVID-19 大流行的緊迫性、各種新突變株的檢測以及未來新冠狀病毒的潛在重新出現，伊維菌素等已批准藥物的再利用可能值得關注。這篇循證綜述文章旨在討論伊維菌素對抗 SARS-CoV-2 的作用機制並總結多年來的可用文獻。已經提出了伊維菌素、宿主細胞和 SARS-CoV-2 在 COVID-19 發病機制和並發症預防中的關鍵細胞和生物分子相互作用的示意圖。